Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria

被引：0
|
作者：
Chetty, Ashwin K.
Khunte, Mihir
Lu, Yuan
Chen, Alissa S.
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[3] Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Yale Sch Med, Dept Internal Med, Natl Clinician Scholars Program, New Haven, CT USA
来源：
AMERICAN HEART JOURNAL | 2024年 / 278卷
关键词：
obesity; prediabetes; semaglutide;
D O I：
10.1016/j.ahj.2024.09.026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0057
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Influence of baseline characteristics on weight loss with semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes (STEP 2)
    Le Roux, C. W.
    Faerch, L.
    Holst-Hansen, T.
    Koroleva, A.
    Kushner, R. F.
    Lim, S.
    Lingvay, I.
    Mosenzon, O.
    Wadden, T. A.
    Garvey, W. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 235 - 236
  • [22] Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)
    Lingvay, Ildiko
    Faerch, Louise
    Koroleva, Anna
    Kushner, Robert F.
    Le Roux, Carel
    Lim, Soo
    Mosenzon, Ofri
    Wadden, Thomas A.
    Wallenstein, Signe O. R.
    Timothy Garvey, W.
    DIABETES, 2021, 70
  • [23] HEALTH UTILITY VALUES IN THE STEP 1-4 TRIALS OF SEMAGLUTIDE 2.4 MG IN OBESITY
    Meincke, H.
    Bjorner, J. B.
    Hansen, T.
    Grand, T. S.
    VALUE IN HEALTH, 2022, 25 (01) : S240 - S240
  • [24] Weight Loss Outcomes with Semaglutide 2.4 mg in Moderate or Severe Obesity in STEP 1 and 2
    Le Roux, Carel
    Aminian, Ali
    Batterham, Rachel
    Hesse, Dan
    Jensen, Camilla
    McGowan, Barbara
    Pakseresht, Arash
    Rigas, Georgia
    Rubino, Francesco
    Taheri, Shahrad
    Morton, John
    OBESITY, 2021, 29 : 46 - 46
  • [25] Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial
    Bliddal, Henning
    Bays, Harold
    Czernichow, Sebastien
    Hemmingsson, Joanna U.
    Hjelmesaeth, Joran
    Morville, Thomas H.
    Koroleva, Anna
    Neergaard, Jesper S.
    Wharton, Sean
    Wizert, Alicja
    Kristensen, Lars Erik
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 (06) : 745 - 746
  • [26] Semaglutide 2.4 mg improves patient-reported outcome measures of physical functioning in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial
    Wharton, S.
    Meincke, H. H.
    Kushner, R. F.
    Oral, T. K.
    Pedersen, S. D.
    Rubino, D. M.
    Ryan, D. H.
    Zeuthen, N.
    Kolotkin, R. L.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 248 - 248
  • [27] IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL
    Verma, Subodh
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John
    Garvey, Tim
    Kushner, Robert
    Rubino, Domenica M.
    Khalid, Usman
    Zeuthen, Niels
    Kosiborod, Mikhail
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1606 - 1606
  • [28] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Batterham, Rachel L.
    Garvey, W. Timothy
    OBESITY, 2023, 31 (09) : 2249 - 2259
  • [29] US POPULATION ELIGIBILITY AND ESTIMATED IMPACT OF SEMAGLUTIDE TREATMENT ON OBESITY PREVALENCE AND CARDIOVASCULAR DISEASE EVENTS IN US ADULTS
    Wong, Nathan D.
    Karthikeyan, Hridhay
    Fan, Wenjun
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1815 - 1815
  • [30] TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL
    Kosiborod, Mikhail
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John
    Garvey, Tim
    Khalid, Usman
    Kushner, Robert
    Rubino, Domenica M.
    Zeuthen, Niels
    Verma, Subodh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1626 - 1626
12345